Top Clinical Trials companies in Switzerland by EBIT
This ranking features the top 4 Clinical Trials companies in Switzerland ranked by EBIT, totalling a EBIT of USD -289.52 M, for January 15, 2025.
Switzerland
Clinical Trials
EBIT
# |
Name |
EBIT |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD -11.81 M
|
Dec. 31, 2023 | USD 2.03 | -1.93% |
|
Switzerland |
|
| 2 |
USD -54.12 M
|
Dec. 31, 2023 | USD 46.50 | 2.74% |
|
Switzerland |
|
| 3 |
USD -73.56 M
|
Dec. 31, 2023 | USD 5.48 | 3.60% |
|
Switzerland |
|
| 4 |
USD -150.03 M
|
Dec. 31, 2023 | USD 1.71 | -0.58% |
|
Switzerland |
Frequently Asked Questions
-
Which Clinical Trials company in Switzerland has the highest EBIT ?
The Clinical Trials company in Switzerland with the highest EBIT is NLS Pharmaceutics AG (NasdaqCM: NLSP) at USD -11.81 M.
-
Which Clinical Trials company in Switzerland has the lowest EBIT ?
The Clinical Trials company in Switzerland with the lowest EBIT is ADC Therapeutics SA (NYSE: ADCT) at USD -150.03 M.
-
What are the top 10 Clinical Trials companies in Switzerland by EBIT ?
The top 10 Clinical Trials companies in Switzerland by EBIT are NLS Pharmaceutics AG, MoonLake Immunotherapeutics, Molecular Partners AG and ADC Therapeutics SA.
-
What are the bottom 10 Clinical Trials companies in Switzerland by EBIT ?
The bottom 10 Clinical Trials companies in Switzerland by EBIT are ADC Therapeutics SA, Molecular Partners AG, MoonLake Immunotherapeutics and NLS Pharmaceutics AG.